ContraFect to Present at the 4th Annual Re-entering Antibacterial Discovery and Development Summit
October 17 2017 - 7:00AM
ContraFect Corporation (NASDAQ:CFRX), a biotechnology company
focused on the discovery and development of protein and antibody
therapeutics for life-threatening, drug-resistant infectious
diseases, today announced that Raymond Schuch, Ph.D., Vice
President of Research at ContraFect, will speak at the Targeting
Gram-Negative Pathogens track of the Re-entering Antibacterial
Discovery and Development Summit, to be held on October 18-20 in
Boston, MA.
“We are pleased to be invited to present highlights of
ContraFect’s Gram-negative lysin discovery program which targets
antibiotic resistant Gram negative bacteria, in particular
Pseudomonas aeruginosa (P. aeruginosa), a highly virulent pathogen
responsible for significant morbidity and mortality despite
currently available treatments,” said Cara Cassino, M.D., EVP of
Research and Development and Chief Medical Officer at
ContraFect.
Presentation Details:
Presentation Title: Development of
Lysins to Target and Kill Gram-Negative Bacterial
Pathogens
Session Day & Time: Friday, October 20,
2017 3:10 PM – 3:40 PM ET
About ContraFect:
ContraFect is a biotechnology company focused on discovering and
developing therapeutic protein and antibody products for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our lysin and monoclonal
antibody platforms to target conserved regions of either bacteria
or viruses (regions that are not prone to mutation). ContraFect's
initial product candidates include new agents to treat
antibiotic-resistant infections such as MRSA (Methicillin-resistant
Staphylococcal aureus) and influenza. The Company’s lead lysin,
CF-301, is currently being studied in a Phase 2 multicenter,
multinational, randomized, controlled clinical trial in patients
with Staphylococcal aureus (Staph aureus) bacteremia including
endocarditis. ContraFect is also conducting research focused on the
discovery of lysins to target Gram-negative bacteria.
About Lysins:
Lysins are enzymes derived from naturally occurring
bacteriophage, viruses which infect bacteria. When produced in
recombinant form and applied to bacteria, lysins cleave a key
component in the structure of the bacterial peptidoglycan cell wall
which results in rapid killing of the target bacteria. ContraFect’s
lead lysin candidate CF-301, has demonstrated a rapid and potent
ability to kill Staph aureus bacteria in vitro and in animal
studies and is the first compound in this new class of
antibacterial agents to enter Phase 2 of clinical development in
the United States.
About Gram-negative Infections:
The 2013 CDC report on Antibiotic Resistance Threats identifies
several Gram-negative pathogens including Enterobacteriaceae (a
family that includes Escherichia coli and Klebsiella spp.), P.
aeruginosa, and Acinetobacter spp. as among the most worrisome
because of strains that are resistant to all or nearly all
available antibiotics. In particular, the CDC classifies
Carbapenem-resistant Enterobacteriaceae (CRE) as an "Urgent" threat
and multi-drug resistant P. aeruginosa and Acinetobacter spp. as
"Serious" threats. Bacteria are generally classified as either
Gram-positive or Gram-negative based on their staining in the
"Gram" strain test. In March, 2017, ContraFect was selected to
receive a funding award from the Combating Antibiotic Resistant
Bacteria Biopharmaceutical Accelerator (CARB-X) to help accelerate
ContraFect's development of lysin therapeutics to treat invasive
infections caused by drug resistant strains of P. aeruginosa, a
potentially life threatening Gram-negative pathogen.
Forward-Looking Statements
This press release contains, and our officers and
representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding our ability to
discover and develop protein and antibody therapeutics for
life-threatening, drug-resistant infectious diseases, our ability
to address life threatening infections using our therapeutic
product candidates from our lysin and monoclonal antibody platforms
to target conserved regions of either bacteria or viruses, whether
our initial product candidates can treat antibiotic-resistant
infections such as MRSA (Methicillin-resistant Staph aureus) and
influenza, our ability to discover and develop new lysins targeting
antibiotic resistant Gram-negative bacteria, particularly P.
aeruginosa, and whether the CARB-X funding will accelerate the
discovery and development of those Gram-negative lysins.
Forward-looking statements are statements that are not historical
facts, nor assurances of future performance. Instead, they are
based on ContraFect’s current beliefs, expectations and assumptions
regarding the future of its business, future plans, strategies,
projections, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent risks, uncertainties and
changes in circumstances that are difficult to predict and many of
which are beyond ContraFect’s control, including those detailed in
ContraFect's filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in
the forward-looking statements. Important factors that could cause
actual results to differ include, among others, our ability to
develop treatments for drug-resistant infectious diseases. Any
forward-looking statement made by ContraFect in this press release
is based only on information currently available and speaks only as
of the date on which it is made. Except as required by applicable
law, ContraFect expressly disclaims any obligations to publicly
update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Investor Relations Contact Paul Boni
ContraFect Corporation Tel: 914-207-2300
Email: pboni@contrafect.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024